Abstract 1569P
Background
Today Breast cancer is the most commonly diagnosed cancer in women in India. Not only India has seen increasing incidence of breast cancer but also there is increase in mortality rate. While majority of patients in western nations are diagnosed in stage I or stage II, almost half of the patients in India present at a advanced stage. Though government authorities are doing their best to address this issue and community workers like Accredited Social health Activists and Auxillary Nurse Midwife have made significant impact, a large proportion of patients remain out of reach. Other methods need to be explored to be able to diagnose larger number of patients at an early stage.
Methods
A cross sectional study was conducted in south 24 paraganas, a rural district of West Bengal in India. 150 medical practioners practicing alternative medicine were enrolled in the study. Paper based case report forms were used and data was later entered into Excel sheets. Questionnaire recorded reasons for late presentation of patients, social, cultural and spiritual beliefs about the disease, economic impact, possible solution and what issues these practioners face in addressing these issues. Also these practioners were assessed as to how they examine and manage patients at their clinic.
Results
92% of practioners did not know how to examine breast lump and identify signs of malignancy 17% believed cancer is an incurable disease 26% were unaware of an oncologist and refer patients to general medical practioner 38% stated loss of daily wages and huge expenses in treatment were main reasons why patients delay treatment 11% stated stigma associated with surgery of breast and chemotherapy results in treatment avoidance.
Conclusions
Reasons for secondary delay in breast cancer diagnosis is multifactorial. Issues both among patients and practioners needs to be addressed. These practitioners are 1st line of contact for many of these patients and trusted by many. A network of these practioners can be built and they can be trained to examine and triage patients. Creation of referreal pathways to nearest oncology center, web or app based training and support programs, awareness about the disease and its management along with provision for financial assistance is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Netaji Subhash Chandra Bose Cancer Research Institute.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10